Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

Inclusion criteria

• Age ≥18 years and ≤75 years.
• Histologically or cytologically confirmed CLDN18.2 positive patients with advanced gastric cancer or pancreatic cancer who failed standard therapy .
• There are assessable lesions according to RECIST V1.1 (solid tumor efficacy evaluation criteria).
• Expected survival time ≥12 weeks.
• ECOG PS 0~1.

Exclusion criteria

• Participating in another interventional clinical study, other than observational (non-interventional) clinical study or in the survival follow-up phase of the interventional study.
• Received any antitumor drug within 2 weeks prior to apheresis or initial administration of the investigational drug.
• Use of immunosuppressive drugs within 1 week prior to apheresis or 2 weeks prior to initial administration of the investigational drug.
• Long-term systemic steroid or any other immunosuppressive drug therapy is required, not including inhaled steroid therapy.
• Receive live attenuated vaccine within 4 weeks prior to initial administration of the study drug or plan to receive live attenuated vaccine during the study period.
• Toxicity (excluding alopecia, fatigue, and hematological toxicity) that did not return to equal to or lower than Grade 1 of NCI CTCAE V5.0 from previous antitumor therapy prior to initial administration of the investigational drug.